cl 387785 and pd168393

cl 387785 has been researched along with pd168393 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, R; DeBlanc, R; Discafani, C; Greenberger, LM; Gruber, BC; Johnson, BD; Koehn, FE; Mamuya, N; Nilakantan, R; Reich, MF; Shen, R; Tsou, HR; Wang, YF; Wissner, A; Ye, F	1
Da Settimo, F; La Motta, C; Martinelli, A; Nerini, E; Sartini, S; Tuccinardi, T	1
Barf, T; Kaptein, A	1

Reviews

1 review(s) available for cl 387785 and pd168393

Article	Year
Irreversible protein kinase inhibitors: balancing the benefits and risks. Journal of medicinal chemistry, 2012, Jul-26, Volume: 55, Issue:14 Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors	2012

Other Studies

2 other study(ies) available for cl 387785 and pd168393

Article	Year
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. Journal of medicinal chemistry, 2001, Aug-16, Volume: 44, Issue:17 Topics: Administration, Oral; Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Female; Fluorometry; Glutathione; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Models, Molecular; Phosphorylation; Precipitin Tests; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Tumor Cells, Cultured	2001
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. Journal of medicinal chemistry, 2009, Feb-26, Volume: 52, Issue:4 Topics: Computational Biology; Computer Simulation; Databases, Protein; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Protein Binding; Quantitative Structure-Activity Relationship	2009

Article

Year

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

Journal of medicinal chemistry, 2001, Aug-16, Volume: 44, Issue:17

Topics: Administration, Oral; Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Female; Fluorometry; Glutathione; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Models, Molecular; Phosphorylation; Precipitin Tests; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Tumor Cells, Cultured

2001

Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.

Journal of medicinal chemistry, 2009, Feb-26, Volume: 52, Issue:4

Topics: Computational Biology; Computer Simulation; Databases, Protein; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Protein Binding; Quantitative Structure-Activity Relationship

2009